KCM
CTMX icon

Kynam Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Kynam Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.6M Buy
15,013,093
+6,047,016
+67% +$30.7M 4.35% 7
2025
Q4 		$38.2M Buy
8,966,077
+5,319,574
+146% +$20.2M 2.44% 11
2025
Q3 		$11.6M Buy
3,646,503
+1,492,090
+69% +$3.36M 0.87% 23
2025
Q2 		$4.89M Buy
+2,154,413
New +$3.47M 0.53% 21

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Kynam Capital Management's CTMX Position: Q1 2026 in Review

Kynam Capital Management increased its CytomX Therapeutics (CTMX) stake by 67% in Q1 2026, buying an estimated $30.7M and bringing the position to 15,013,093 shares worth $70.6M. The position accounts for 4.35% of the portfolio, ranked #7.

Kynam Capital Management first reported a position in CTMX in Q2 2025 and has held it in 4 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Kynam Capital Management held 15,013,093 shares of CytomX Therapeutics worth $70.6M as of Q1 2026.
  • Kynam Capital Management bought 6,047,016 CytomX Therapeutics shares in Q1 2026, an estimated $30.7M.
  • CytomX Therapeutics made up 4.35% of Kynam Capital Management's portfolio in Q1 2026, its #7 holding.
  • Kynam Capital Management first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.